Swiss Experience in Therapy With Dual Bronchodilation in Chronic Obstructive Pulmonary Disease in Relation to Self-Reported Physical Functionality

Marc Spielmanns, Michael Tamm, Sebastian Schildge, Arschang Valipour, Marc Spielmanns, Michael Tamm, Sebastian Schildge, Arschang Valipour

Abstract

Background: Medical therapy in chronic obstructive pulmonary disease (COPD) usually includes inhaled dual bronchodilation leading not only to an improvement in symptoms but also to an increase in physical performance. However, it remains unknown whether responder rates to dual bronchodilation differ between the Swiss subgroup in comparison to participants of other European countries.

Methods: The non-interventional OTIVACTO trial investigated changes in self-reported physical functioning in COPD patients treated with tiotropium/olodaterol 5/5 µg fixed dose combination for 6 weeks. The cut-off between responder and non-responder was defined as a minimum increase of 10 points using the 10-question physical functioning questionnaire (PF-10) score. We searched for patterns of the responder patient group and compared the results of the whole dataset with the subgroup of Swiss participants.

Results: Compared to the total cohort (n = 7,608), the Swiss participants (n = 94) were predominantly > 65 years of age and had significantly more comorbidities. There were no significant differences according to COPD stage, smoking status, exacerbation rate in the last 12 months and modified Medical Research Council questionnaire (mMRC) score between the total cohort and the Swiss collective. There were no significant differences between the Swiss subgroup and the total cohort with regard to response to the medication in the PF-10 score. In the intragroup comparison, patients with high mMRC score showed significantly higher values in the PF-10 in both groups. The number of exacerbations had no influence on the PF-10 score in the Swiss subgroup but in the total cohort.

Conclusion: In terms of age and number of comorbidities, significant differences were found between the overall patient population and the Swiss participants, having no influence on the success of the medication. The patients suffering from increased dyspnea benefited most from tiotropium/olodaterol treatment (Clinical Trials Registry NCT02720757).

Keywords: COPD; Olodaterol; PF-10; Physical functioning; Tiotropium bromide.

Conflict of interest statement

None to declare.

Copyright 2021, Spielmanns et al.

Figures

Figure 1
Figure 1
Pearson correlation analysis of change in PF-10 and mMRC in Switzerland. PF-10: 10-question physical functioning questionnaire; mMRC: modified Medical Research Council questionnaire.
Figure 2
Figure 2
Pearson correlation analysis of change in PF-10 and exacerbations in the last 12 months in Switzerland. PF-10: 10-question physical functioning questionnaire.
Figure 3
Figure 3
Pearson correlation analysis of change in PF-10 and mMRC in other countries. PF-10: 10-question physical functioning questionnaire; mMRC: modified Medical Research Council questionnaire.
Figure 4
Figure 4
Pearson correlation analysis of change in PF-10 and exacerbations in the last 12 months in other countries. PF-10: 10-question physical functioning questionnaire.

References

    1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–149. doi: 10.1016/j.arbres.2017.02.001.
    1. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596.
    1. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, Rengo F. et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J. 2003;22(3):444–449. doi: 10.1183/09031936.03.00101203.
    1. Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G. et al. Differential effect of modified medical research council dyspnea, COPD assessment test, and clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD. Chest. 2015;148(1):159–168. doi: 10.1378/chest.14-2449.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. Available from: . Accessed July 17, 2020.
    1. O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W. et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348. doi: 10.1183/13993003.01348-2016.
    1. Troosters T, Maltais F, Leidy N, Lavoie KL, Sedeno M, Janssens W, Garcia-Aymerich J. et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032. doi: 10.1164/rccm.201706-1288OC.
    1. Thomas M, Decramer M, O'Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22(1):101–111. doi: 10.4104/pcrj.2013.00025.
    1. Maltais F, O'Donnell D, Galdiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K. et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1753465818755091. doi: 10.1177/1753465818755091.
    1. Valipour A, Tamm M, Kocianova J, Bayer V, Sanzharovskaya M, Medvedchikov A, Haaksma-Herczegh M. et al. Improvement in self-reported physical functioning with tiotropium/olodaterol in central and eastern European COPD Patients. Int J Chron Obstruct Pulmon Dis. 2019;14:2343–2354. doi: 10.2147/COPD.S204388.
    1. Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H. et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637. doi: 10.1183/13993003.01170-2015.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002.
    1. Cohen J, editor. Statistical power analysis for the behavioral sciences, 1st ed. Hillsdale (NJ): Lawrence Erlbaum Associates Inc.; 1977.
    1. Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat(R) improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:367–373. doi: 10.2147/COPD.S14082.
    1. Coronel C, Orozco-Levi M, Ramirez-Sarmiento A, Martinez-Llorens J, Broquetas J, Gea J. [Low-weight syndrome associated with COPD in our setting] Arch Bronconeumol. 2002;38(12):580–584. doi: 10.1016/S0300-2896(02)75294-0.
    1. Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378. doi: 10.1016/S2213-2600(18)30054-7.
    1. Huang WC, Wu MF, Chen HC, Hsu JY, Taiwan Obstructive Lung Disease C. Characteristics and risk factors for inconsistency between the risk of exacerbations and the severity of airflow limitation in COPD based on GOLD 2017: A retrospective, cross-sectional study. PLoS One. 2018;13(3):e0193880. doi: 10.1371/journal.pone.0193880.
    1. Ding B, Judge D, Small M, Bent-Ennakhil N, Siddiqui S. Functional performance in patients with COPD: association with treatment regimen, GOLD group, lung function, and symptom burden in a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2018;13:2785–2796. doi: 10.2147/COPD.S170391.
    1. Miravitlles M, Worth H, Soler Cataluna JJ, Price D, De Benedetto F, Roche N, Godtfredsen NS. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122. doi: 10.1186/s12931-014-0122-1.
    1. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, Criner GJ. et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi: 10.1164/rccm.202003-0625ST.
    1. Muller C, Winter C, Rosenbaum D. Current objective techniques for physical activity assessment in comparison with subjective methods. Dtsch Z Sportmed. 2010;61(1):11–18.
    1. Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S. et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–1337. doi: 10.2147/COPD.S133307.
    1. Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X. et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–1237. doi: 10.2147/COPD.S159732.
    1. Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R. et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19(1):121. doi: 10.1186/s12931-018-0830-z.
    1. Spielmanns M, Gloeckl R, Schmoor C, Windisch W, Storre JH, Boensch M, Kenn K. Effects on pulmonary rehabilitation in patients with COPD or ILD: A retrospective analysis of clinical and functional predictors with particular emphasis on gender. Respir Med. 2016;113:8–14. doi: 10.1016/j.rmed.2016.02.006.
    1. Hayata A, Minakata Y, Matsunaga K, Nakanishi M, Yamamoto N. Differences in physical activity according to mMRC grade in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2203–2208. doi: 10.2147/COPD.S109694.
    1. Ariel A, Altraja A, Belevskiy A, Boros PW, Danila E, Flezar M, Koblizek V. et al. Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. Int J Chron Obstruct Pulmon Dis. 2018;13:45–56. doi: 10.2147/COPD.S145573.
    1. Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Flezar M. et al. How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2017;196(2):139–149. doi: 10.1164/rccm.201609-1794CI.
    1. Steinmetz KO, Abenhardt B, Pabst S, Hansel M, Kondla A, Bayer V, Buhl R. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat((R)) in patients with COPD in a real-world clinical setting. Int J Chron Obstruct Pulmon Dis. 2019;14:1441–1453. doi: 10.2147/COPD.S195852.
    1. Molina Paris J, Alonso Hernandez PM, Diez Garcia JA, Gonzalez Uribe-Etxebarria I, Yelo Garcia J, Galera Llorca J, Aguilar H. et al. Assessment of physical functioning in patients with chronic obstructive pulmonary disease (COPD) requiring long-acting dual bronchodilation in routine clinical practice. Semergen. 2020;S1138-3593(20):30402-0. doi: 10.1016/j.semerg.2020.10.006.
    1. ten Klooster PM, Oude Voshaar MA, Gandek B, Rose M, Bjorner JB, Taal E, Glas CA. et al. Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis. Health Qual Life Outcomes. 2013;11:199. doi: 10.1186/1477-7525-11-199.
    1. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79. doi: 10.1186/1465-9921-11-79.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться